Essential Pharma strengthens rare disease portfolio with acquisition of Ventavis® (iloprost trometamol) for adult primary pulmonary hypertension

Ventavis® is an established inhaled prostacyclin analogue for the treatment of primary pulmonary hypertension Acquisition reinforces Essential Pharma’s mission to serve the needs of rare disease populations and enhances reputation as a trusted partner for continued access to niche medicines   Egham, UK – 17 February 2026 – Essential Pharma (“Essential” or “the Company”), a […]